en · de · es · pt
epitalon-notes.peptides8425.com › Blog › Epitalon Peptide Background And Structure — Evidence Review

Epitalon Peptide Background And Structure — Evidence Review

By Editorial Desk · published 2026-07-30 · last reviewed 2026-08-01 · Blog

This is a working overview of HPLC purity, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Epitalon Peptide Background and Structure

The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.

The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.

Research Claims and Evidence Status

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

Epitalon at a glance

PropertyValueNotes
Amino acid sequenceAla-Glu-Asp-GlyTetrapeptide, often abbreviated AEDG
Molecular formulaC14H22N4O9Free peptide, unmodified termini
Molecular weight~390.35 DaCalculated for the free acid form
AppearanceWhite to off-white powderTypical lyophilized product form
Solubility classFreely soluble in waterTwo acidic residues dominate ionic character

Peptide Identity and Laboratory Handling

Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.

Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.

Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.

Related pages on this site

Analytical Verification and Storage

Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.

The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.

Epitalon Structure and Research Origin

Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.

Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.

Further detail

1 July Scientists show why climate benefits from nature restoration are "dwarfed by the scale of ongoing fossil fuel emissions". A new CRISPR gene editing/repair tool alternative to fully active Cas9 is reported – Cas9-derived nickases mediated homologous chromosome-templated repair, applicable to organisms whose matching chromosome has the desired gene/s, which is demonstrated to be more effective than Cas9 and cause fewer off-target edits. 4 July – Scientists report that heatwaves in western Europe are increasing "three-to-four times faster compared to the rest of the northern midlatitudes over the past 42 years" and that certain atmospheric dynamical changes can explain their increase. 5 July – The Large Hadron Collider commences its Run 3 physics season. The LHCb collaboration observes three never-before-seen particles: a new kind of "pentaquark" and the first-ever pair of "tetraquarks", which includes a new type of tetraquark. Scientists based in Bengaluru’s Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) have found a novel substance termed “single-crystalline scandium nitride” that can transform infrared light into renewable energy. 6 July – A study suggests that the marginal effectiveness of a fourth COVID-19 vaccine dose (a second "booster") versus three doses can be 40% (24% to 52%) against severe disease outcomes. There is no scientific consensus about the efficacy and overall recommendabilities of a fourth dose. The CDC recommended such in March only for "certain immunocompromised individuals and people over the age of 50".

== History == The coupling of chromatography with MS is a well developed chemical analysis strategy dating back from the 1950s. Gas chromatography (GC)–MS was originally introduced in 1952, when A. T. James and A. J. P. Martin were trying to develop tandem separation – mass analysis techniques. In GC, the analytes are eluted from the separation column as a gas and the connection with electron ionization (EI) or chemical ionization (CI) ion sources in the MS system was a technically simpler challenge. Because of this, the development of GC-MS systems was faster than LC–MS and such systems were first commercialized in the 1970s. The development of LC–MS systems took longer than GC-MS and was directly related to the development of proper interfaces. Victor Talrose and his collaborators in Russia started the development of LC–MS in the late 1960s, when they first used capillaries to connect an LC column to an EI source. A similar strategy was investigated by McLafferty and collaborators in 1973 who coupled the LC column to a CI source, which allowed a higher liquid flow into the source. This was the first and most obvious way of coupling LC with MS, and was known as the capillary inlet interface. This pioneer interface for LC–MS had the same analysis capabilities of GC-MS and was limited to rather volatile analytes and non-polar compounds with low molecular mass (below 400 Da). In the capillary inlet interface, the evaporation of the mobile phase inside the capillary was one of the main issues.

== Enzyme diffusivity == The advent of single-molecule studies in the 2010s led to the observation that the movement of untethered enzymes increases with increasing substrate concentration and increasing reaction enthalpy. Subsequent observations suggest that this increase in diffusivity is driven by transient displacement of the enzyme's center of mass, resulting in a "recoil effect that propels the enzyme".

Sources: en.wikipedia.org

Supporting material

Spectrin (alpha and beta) Ankyrin Band-3 protein Protein-4.2 Lesser proteins of significance Hereditary spherocytosis can be an autosomal recessive or autosomal dominant trait. The autosomal recessive inheritance pattern accounts for close to 25% of the clinical cases. The autosomal dominant inheritance pattern accounts for over 75% of the clinical cases. Many positive individuals will not present clinically, thus the etiologic data may be artificially skewed towards the more prominent dominant forms. These dominant forms tend to leave a family history that yields generational splenectomies and black gallstones cholelithiasis. Lastly, an estimated 25% of cases are due to spontaneous mutations.

== Technology and product offerings == Seer's proteomics platform integrates engineered nanoparticles, automated sample preparation, and mass spectrometry. It utilizes nanoparticles with different physicochemical properties, including size, charge, and hydrophobicity, to separate and enrich proteins from biological samples, thereby addressing common issues related to dynamic range and sample complexity in proteomics. Seer's platform enables deep, unbiased proteomic analysis, allowing researchers to identify proteins associated with disease or therapeutic response without relying on prior assumptions. A 2020 study published in Nature Communications demonstrated that these nanoparticles form distinct protein coronas, enabling high-depth, parallel profiling of the plasma proteome. Independent benchmark studies indicate that nanoparticle-based plasma proteomics workflows significantly enhance proteome depth and improve quantitative precision when compared to traditional neat-plasma methods. These studies report approximately 3 to 6 times more protein identifications and about twice the reproducibility in independent side-by-side experiments. As of 2025, 58 papers have been published related to the Proteograph, including in journals such as Nature, Nature Communications, Nature Aging, and Cell Metabolism. Among these, a 2025 Nature Aging study reported the identification of more than 10,000 proteins, underscoring the Proteograph platform’s depth in studies at scale.

== History == The U.S. Food and Drug Administration (FDA) approved vericiguat based on evidence from a clinical trial (NCT02861534) which consisted of 5,050 participants aged 23 to 98 years old with worsening heart failure. The trial was conducted at 694 sites in 42 countries in Europe, Asia, North and South America. The trial enrolled participants with symptoms of worsening heart failure. Participants were randomly assigned to receive vericiguat or a placebo pill once a day. Neither the participants nor the health care professionals knew if the participants were given vericiguat or placebo pills until after the trial was complete. It was awarded a fast track designation on 19 January 2021.

Sources: en.wikipedia.org

Supporting material

=== Sustained release === There are several methods by which tablets and capsules can be modified in order to allow for sustained release of the active compound as it passes through the digestive tract. One of the most common methods is to embed the active ingredient in an insoluble porous matrix, such that the dissolving drug must make its way out of the matrix before it can be absorbed. In other sustained release formulations the matrix swells to form a gel through which the drug exits. Another method by which sustained release is achieved is through an osmotic controlled-release oral delivery system, where the active compound is encased in a water-permeable membrane with a laser drilled hole at one end. As water passes through the membrane the drug is pushed out through the hole and into the digestive tract where it can be absorbed.

=== Artificial === De novo designed peptides which self-assemble in the presence of copper (Cu), forming supramolecular assemblies were presented by Korendovych et al. Additionally there are examples of metallopeptides that are, at least partially, composed of non-natural amino acids with possible applications in drug discovery and biomaterials.

=== Polymorphisms === Single nucleotide polymorphisms (SNPs) genetic variations within OPRK1, have been associated with susceptibility to substance use disorders and stress-related behaviors. The G36T SNP (rs1051660) is more frequent in heroin-dependent individuals compared to healthy controls. Other study found an association of OPRK1 variants with cocaine dependence and relapse susceptibility.

Sources: en.wikipedia.org

Frequently asked questions

What is epitalon made of?

Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.

Is epitalon extracted from the pineal gland?

No. Epitalon is chemically synthesized, not extracted. It was designed as a short synthetic fragment conceptually related to larger pineal peptides studied in the same research tradition, particularly the extract known as epithalamin. The two are distinct materials with different compositions.

Why is epitalon described as a bioregulator?

The term bioregulator is used in this research tradition for short peptides proposed to influence gene expression or cell function. Epitalon is grouped with other synthetic short peptides under this label. The term reflects a proposed mechanism rather than an established drug classification.

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

Network